Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2007-12-21
2010-06-15
Woodward, Cherie M (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C514S012200
Reexamination Certificate
active
07736639
ABSTRACT:
Methods of treating cancer in patients in need thereof with human interleukin-18 (IL-18) polypeptides and substitution mutants thereof that are conjugated to water-soluble polymers at specific sites on the human IL-18 protein are disclosed.
REFERENCES:
patent: 6893633 (2005-05-01), Hellstrand et al.
patent: 7452536 (2008-11-01), Gorczynski et al.
patent: 2002/0182174 (2002-12-01), Hellstrand et al.
patent: 2007/0212328 (2007-09-01), Bruck et al.
patent: WO 9945026 (1999-09-01), None
Katre et al., (PNAS USA 1987; 84:1487-1491).
Pettit et al., (J Biol Chem 1997 272(4):2312-2318).
Kirkpatrick et al., (Protein Expr Purif Feb. 2003;27(2):279-92).
Fu et al., (Acta Biochimica et Biophysica Sinica 2001; 33(4):368-372).
Kim et al., (J Biol Chem Mar. 29, 2992; 277(13):10998-11003).
Robertson et al., (Clin Canc Res. Jul. 15, 2006;23(14 Pt1):4265-73; Abstract Only).
Robertson et al., (Clin Canc Res. Jun. 1, 2008; 14(11):3462-9).
Jonak et al., (J Immunother. Mar.-Apr. 2002; 25 Suppl 1:S20-7; Abstract Only).
Veronese, F.M., “Peptide and protein PEGylation: a review of problems and solutions,”Biomaterials, vol. 22, pp. 405-417 (2001).
Arase, et al., “Interferon γ Production by Natural Killer (NK) Cells and NK1.1+T Cells upon NKR-P1 Cross-linking,”J. Exp. Med., vol. 183, pp. 2391-2396 (1996).
Jonak, et al., “High-Dose Recombinant Interleukin-18 Induces an Effective TH1 Immune Response to Murine MOPC-315 Plasmacytoma,”Journal of Immunotherapy., vol. 25 (Suppl. 1), pp. S20-S27 (2002).
Robertson, et al., “A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer,”Clin. Cancer Res., vol. 14(11), pp. 3462-3469 (2008).
Robertson, et al., “Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer,”Clin. Cancer Res., vol. 12(4), pp. 4265-4273 (2006).
Tannenbaum, et al., “Immune-inflammatory mechanisms in IFNγ-mediated anti-tumor activity,”Seminars in Cancer Biology, vol. 10, pp. 113-123 (2000).
Vermijlen, et al., “Perforin and granzyme B induce apoptosis in FasL-resistant colon carcinoma cells,”Cancer Immunol. Immunother., vol. 50, pp. 212-217 (2001).
Zamai, et al., “NK Cells and Cancer,”Journal of Immunology, vol. 178, pp. 4011-4016 (2007).
Bam Narendra
Bongers Jacob
Janson Cheryl A.
Johanson Kyung
Jonak Zdenka
GlaxoSmithKline LLC
Han William T.
Hecht Elizabeth J.
Woodward Cherie M
LandOfFree
Method of treating cancer by administering conjugates... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating cancer by administering conjugates..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating cancer by administering conjugates... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4199853